Amgen's Q3 2022 earnings show strong performance despite macroeconomic headwinds.  Key drivers include healthy volume growth, particularly outside the US, and record sales for several products.  Management's optimistic outlook for 2023, with a focus on new launches and biosimilars, suggests a potential positive impact on the stock for the coming weeks as investors react to the consistent strong performance and potential for continued growth in the coming year.


[1]
